{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:54:29Z","timestamp":1783029269102,"version":"3.54.6"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014471","name":"Mundipharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Rezafungin, a novel, once-weekly echinocandin for the treatment of candidemia and\/or invasive candidiasis (IC) was noninferior to caspofungin for day 30 all-cause mortality (ACM) and day 14 global cure in the phase 3 ReSTORE trial (NCT03667690). We conducted preplanned subgroup analyses for patients with a positive culture close to randomization in ReSTORE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>ReSTORE was a multicenter, double-blind, double-dummy, randomized trial in patients aged \u226518 years with candidemia and\/or IC treated with once-weekly intravenous rezafungin (400 mg\/200 mg) or once-daily intravenous caspofungin (70 mg\/50 mg). This analysis comprised patients with a positive blood culture drawn between 12 hours before and 72 hours after randomization or a positive culture from another normally sterile site sampled between 48 hours before and 72 hours after randomization. Efficacy endpoints included day 30 ACM, day 14 global cure rate, and day 5 and 14 mycological response. Adverse events were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This analysis included 38 patients randomized to rezafungin and 46 to caspofungin. In the rezafungin and caspofungin groups, respectively, day 30 ACM was 26.3% and 21.7% (between-group difference [95% confidence interval], 4.6% [\u221213.7%, 23.5%]), day 14 global response was 55.3% and 50.0% (between-group difference, 5.3% [\u221216.1%, 26.0%]), and day 5 mycological eradication was 71.1% and 50.0% (between-group difference, 21.1% [\u22120.2%, 40.2%]). Safety was comparable between treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These findings support the efficacy and safety of rezafungin compared with caspofungin for the treatment of candidemia and\/or IC in patients with a positive culture close to randomization, with potential early treatment benefits for rezafungin.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciae363","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T17:36:07Z","timestamp":1722620167000},"page":"672-681","source":"Crossref","is-referenced-by-count":9,"title":["Treatment Outcomes Among Patients With a Positive<i>Candida<\/i>Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"Alex","family":"Soriano","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona, IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBERINF, CIBER of Infectious Diseases, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-4890","authenticated-orcid":false,"given":"Patrick M","family":"Honore","sequence":"additional","affiliation":[{"name":"CHU UCL Godinne Namur, UCL Louvain Medical School , Campus Godinne, Namur ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne , Cologne ,","place":["Germany"]},{"name":"Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM) and German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, University Hospital Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4582-4914","authenticated-orcid":false,"given":"Methee","family":"Chayakulkeeree","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS San Martino Polyclinic Hospital , Genoa ,","place":["Italy"]},{"name":"Department of Health Sciences (DISSAL), University of Genoa , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3803-5877","authenticated-orcid":false,"given":"Huang","family":"Haihui","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5644-3412","authenticated-orcid":false,"given":"Herv\u00e9","family":"Dupont","sequence":"additional","affiliation":[{"name":"Amiens-Picardie University Hospital , Amiens ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-6265","authenticated-orcid":false,"given":"Young Keun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University Wonju College of Medicine , Wonju ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Kollef","sequence":"additional","affiliation":[{"name":"Washington University , St. Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-8167","authenticated-orcid":false,"given":"Bart Jan","family":"Kullberg","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9325-0323","authenticated-orcid":false,"given":"Nick","family":"Manamley","sequence":"additional","affiliation":[{"name":"Mundipharma Research Limited , Cambridge ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pappas","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pullman","sequence":"additional","affiliation":[{"name":"Mercury Street Medical , Butte, Montana ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Sandison","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc. , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-6183","authenticated-orcid":false,"given":"Cecilia","family":"Dignani","sequence":"additional","affiliation":[{"name":"PSI-CRO , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-819X","authenticated-orcid":false,"given":"Jose A","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Augusta University , Augusta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-5750","authenticated-orcid":false,"suffix":"III","given":"George R","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of California Davis Medical Center , Sacramento, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"2024092615372190300_ciae363-B1","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1093\/cid\/ciaa193","article-title":"Burden of candidemia in the United States, 2017","volume":"71","author":"Tsay","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024092615372190300_ciae363-B2","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2024092615372190300_ciae363-B3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","article-title":"Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project","volume":"23","author":"Bassetti","year":"2019","journal-title":"Crit Care"},{"key":"2024092615372190300_ciae363-B4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/cid\/ciac004","article-title":"Attributable mortality of Candida bloodstream infections in the modern era: a propensity score analysis","volume":"75","author":"Mazi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024092615372190300_ciae363-B5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vhri.2019.07.002","article-title":"The economic burden of candidemia and invasive candidiasis: a systematic review","volume":"21","author":"Wan Ismail","year":"2020","journal-title":"Value Health Reg Issues"},{"key":"2024092615372190300_ciae363-B6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024092615372190300_ciae363-B7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2024092615372190300_ciae363-B8","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092615372190300_ciae363-B9","author":"European Medicines Agency"},{"key":"2024092615372190300_ciae363-B10","author":"US Food and Drug Administration"},{"key":"2024092615372190300_ciae363-B11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin\u2014mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2024092615372190300_ciae363-B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fmb-2020-0217","article-title":"Rezafungin: a novel antifungal for the treatment of invasive candidiasis","volume":"16","author":"Ham","year":"2021","journal-title":"Future Microbiol"},{"key":"2024092615372190300_ciae363-B13","doi-asserted-by":"crossref","first-page":"e01627\u201316","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092615372190300_ciae363-B14","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/cmi.12640","article-title":"CD101: a novel long-acting echinocandin","volume":"18","author":"Zhao","year":"2016","journal-title":"Cell Microbiol"},{"key":"2024092615372190300_ciae363-B15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/jof6040192","article-title":"Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data","volume":"6","author":"Zhao","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2024092615372190300_ciae363-B16","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024092615372190300_ciae363-B17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2024092615372190300_ciae363-B18","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2024092615372190300_ciae363-B19","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024092615372190300_ciae363-B20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024092615372190300_ciae363-B21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2024092615372190300_ciae363-B22","doi-asserted-by":"crossref","first-page":"e00758\u201317","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092615372190300_ciae363-B23","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1128\/AAC.47.4.1179-1186.2003","article-title":"In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092615372190300_ciae363-B24","doi-asserted-by":"crossref","first-page":"e01009\u201317","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092615372190300_ciae363-B25","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.jval.2023.09.599","article-title":"Cost-effectiveness of once-weekly rezafungin for the treatment of candidemia and invasive candidiasis in the UK [abstract]","volume":"26","author":"Muszbek","year":"2023","journal-title":"Value Health"},{"key":"2024092615372190300_ciae363-B26","doi-asserted-by":"crossref","first-page":"dlad079","DOI":"10.1093\/jacamr\/dlad079","article-title":"Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis","volume":"5","author":"Jeck","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"2024092615372190300_ciae363-B27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/myc.13290","article-title":"Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: a systematic review and network meta-analysis","volume":"64","author":"Demir","year":"2021","journal-title":"Mycoses"},{"key":"2024092615372190300_ciae363-B28","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/jac\/dkx448","article-title":"We can do better: a fresh look at echinocandin dosing","volume":"73","author":"Bader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024092615372190300_ciae363-B29","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/jac\/dkx447","article-title":"Overview of antifungal dosing in invasive candidiasis","volume":"73","author":"Pea","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024092615372190300_ciae363-B30","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092615372190300_ciae363-B31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2024092615372190300_ciae363-B32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/jac\/dkr511","article-title":"Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes","volume":"67","author":"Grim","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2024092615372190300_ciae363-B33","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/cis305","article-title":"Septic shock attributed to Candida infection: importance of empiric therapy and source control","volume":"54","author":"Kollef","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024092615372190300_ciae363-B34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/13693786.2010.512300","article-title":"Early treatment of candidemia in adults: a review","volume":"49","author":"Ostrosky-Zeichner","year":"2011","journal-title":"Med Mycol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae363\/58721368\/ciae363.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/3\/672\/59357077\/ciae363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/3\/672\/59357077\/ciae363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T17:32:58Z","timestamp":1732383178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/3\/672\/7710608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,7,10]]},"published-print":{"date-parts":[[2024,9,26]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae363","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9,15]]},"published":{"date-parts":[[2024,7,10]]}}}